Definium Therapeutics Sees Unusually Large Options Volume (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the recipient of some unusual options trading on Friday. Stock traders acquired 9,041 call options on the stock. This is an increase of approximately 292% compared to the average volume of 2,306 call options.

Insider Buying and Selling

In other news, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 48,096 shares of company stock worth $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Boxer Capital Management LLC bought a new position in Definium Therapeutics in the 3rd quarter valued at about $1,928,000. Rosalind Advisors Inc. boosted its holdings in shares of Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares during the period. Royal Bank of Canada grew its position in shares of Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Definium Therapeutics in the third quarter valued at approximately $379,000. Finally, Blair William & Co. IL increased its stake in shares of Definium Therapeutics by 43.6% during the third quarter. Blair William & Co. IL now owns 31,905 shares of the company’s stock worth $376,000 after purchasing an additional 9,687 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Stock Down 5.1%

Shares of DFTX traded down $2.46 during midday trading on Friday, hitting $45.99. The stock had a trading volume of 1,045,828 shares, compared to its average volume of 2,330,113. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of -18.47 and a beta of 2.20. The company has a 50 day simple moving average of $28.68 and a two-hundred day simple moving average of $21.50. Definium Therapeutics has a twelve month low of $7.76 and a twelve month high of $49.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, analysts anticipate that Definium Therapeutics will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Definium Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 4th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Piper Sandler restated an “overweight” rating and issued a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Finally, JonesTrading raised their price target on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $49.23.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.